Pfizer has not only lost a key patent fight over Lyrica in Britain. It's now under fire for threatening legal action against doctors and pharmacies to enforce that very patent.
The Centers for Disease Control immunization committee stopped short of advising routine vaccination against meningitis B, instead leaving the decision up to doctors and families. And now, U.S. universities are tackling MenB vaccination in a multitude of ways.
Hybrid R&D outfit Evotec signed a deal with Pfizer to collaborate on tissue fibrosis research, lending its expertise and discovery technology to the pharma giant in exchange for a cut of the benefits.
The CDC's Advisory Committee on Immunization Practices has stopped short of recommending routine meningitis B immunization, leaving the decision to doctors and families whether young adults aged 16 to 23 should be vaccinated. Result? U.S. universities are taking varying approaches when it comes to MenB jabs and their students.
Pfizer has been trotting out positive study data to try to convince the FDA to revoke a black-box warning on its smoking cessation drug Chantix tied to serious psychiatric side effects. Now the company is touting a new study which shows that Chantix does not increase certain cardiovascular or psychiatric symptoms and that it should be recommended for more smokers.
India's Patent Office has denied Pfizer additional patents on rheumatoid arthritis medicine Xeljanz by raising questions on whether the new application proved enhanced efficacy, the Economic Times reported.
Just as its acquisition by Pfizer closed, Hospira nabbed a $50 million contract from the U.S. Department of Defense. This injectable drug and infusion tech company was not alone on the DOD list. Philips Healthcare was also awarded an $18.8 million contract in the same Sept. 2 disclosure from the DOD.
A federal judge's inclination means Pfizer could remain in the line of fire to pay out more than $2 billion. That is the potential liability Pfizer faces for a federal lawsuit accusing its Wyeth unit of failing to pay Medicaid rebates for stomach upset drug Protonix.
Johnson & Johnson and Bayer are leading the four-horse race among new-age anticoagulants, and they're hoping some new real-world safety data for Xarelto can help keep the med in the No. 1 spot.
Japan's Ministry of Health, Labor and Welfare last week gave the nod to several new drug indications, including Mitsubishi Tanabe's Remicade for intravenous use and indications of entero-Behcet, neuro-Behcet and vasculo-Behcet diseases when existing treatments are inadequate, a spokesman for the ministry said.